Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,300Price:$7.00
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,500Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Tingley WhittemoreOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:215,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Tingley WhittemoreOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Patterson Leone DOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Patterson Leone DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Ali FarazOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:505,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Ali FarazOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 20, 2024 (filed on Feb 21, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-200Price:$6.17
Filings by filing date
-
Mar 05, 2024 (filed on Mar 06, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,300Price:$7.00
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:75,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:12,500Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Tingley WhittemoreOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:215,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Tingley WhittemoreOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Patterson Leone DOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:205,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Patterson Leone DOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Ali FarazOwnership Type:Direct OwnershipSecurities:Stock Option (Right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:505,000Price:--
-
Feb 23, 2024 (filed on Feb 27, 2024)Insider Name:Ali FarazOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:85,000Price:--
-
Feb 20, 2024 (filed on Feb 21, 2024)Insider Name:Hoey TimothyOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-200Price:$6.17
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 171 Oyster Point Blvd., Suite 500 SOUTH SAN FRANCISCO CA 94080 |
Tel: | N/A |
Website: | https://www.tenayatherapeutics.com |
IR: | See website |
Key People | ||
Faraz Ali Chief Executive Officer, Director | Leone D. Patterson Chief Financial and Business Officer | Timothy Hoey Chief Scientific Officer | Whittemore Tingley Chief Medical Officer |
Business Overview |
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company's advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company's adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction. |
Financial Overview |
For the fiscal year ended 31 December 2023, Tenaya Therapeutics Inc revenues was not reported. Net loss decreased less than 1% to $124.1M. Net income also reflects Interest income increase from $2M to $7.1M (income), Other income (expense), net increase from $2K to $53K (income), offset by Stock-based Compensation in R&D increase of 43% to $7M (expense), Stock-based Compensation in SGA increase of 26% to $8.3M (expense). |
Employees: | 140 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $239.26M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$122.46M as of Dec 31, 2023 |
Net annual income (TTM): | -$124.08M as of Dec 31, 2023 |
Free cash flow (TTM): | -$103.31M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 78,517,534 as of Apr 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |